Trial Profile
CLINICAL TRIAL PHASE IIIb to evaluate predictors of response to linaclotide in patients with irritable bowel syndrome and explore the impact on intestinal symptoms
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 May 2017
Price :
$35
*
At a glance
- Drugs Linaclotide (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Almirall S.A.
- 09 May 2017 Results presented at the Digestive Disease Week 2017
- 09 May 2017 Status changed from recruiting to active, no longer recruiting, according to the results presented at the Digestive Disease Week 2017
- 11 Apr 2014 New trial record